Amneal Pharmaceuticals, Inc. (AMRX) Financial Statements (2026 and earlier)

Company Profile

Business Address
,
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)
Annual | Quarterly

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1119226248341151
Cash and cash equivalent1119226248341151
Restricted cash and investments889962
Receivables910775707669636
Inventory, net of allowances, customer advances and progress billings612581531489491381
Inventory612581531489491381
Prepaid expense404342413435
Contract with customer, asset, after allowance for credit loss222121
Other undisclosed current assets806642272584
Total current assets:1,5881,3781,4121,5201,5521,210
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization    645961
Operating lease, right-of-use asset424356605970
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization425448470514478478
Intangible asset, including goodwill, after accumulated amortization1,3301,4891,6951,7601,8271,802
Goodwill597599599593523420
Intangible asset, excluding goodwill, after accumulated amortization7328901,0961,1671,3051,383
Restricted cash and investments      
Other noncurrent assets6056103213244
Other undisclosed noncurrent assets565963   
Total noncurrent assets:1,9142,0952,3882,4202,4542,456
TOTAL ASSETS:3,5013,4733,7993,9404,0063,666
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:   538583614507
Taxes payable✕✕✕✕369
Employee-related liabilities✕✕✕✕625936
Accounts payable   166131153103
Accrued liabilities   131728077
Other undisclosed accounts payable and accrued liabilities   241316316283
Debt2243430314421
Estimated litigation liability3277107   
Due to related parties✕✕✕24886
Other undisclosed current liabilities87473575151115
Total current liabilities:1,130847753677677550
Noncurrent Liabilities
Long-term debt and lease obligation2,1622,3862,5922,6802,7352,609
Long-term debt, excluding current maturities2,1622,3862,5922,6802,7352,609
Liabilities, other than long-term debt9411147878640
Deferred compensation liability, classified911    
Estimated litigation liability85049   
Due to related parties✕✕✕1048  
Other liabilities   87398640
Other undisclosed noncurrent liabilities16016799112151120
Total noncurrent liabilities:2,4162,5652,8382,8792,9722,769
Total liabilities:3,5463,4113,5903,5563,6493,319
Temporary equity, including noncontrolling interest6541251712 
Equity
Equity, attributable to parent, including:(109)20298360303232
Additional paid in capital560539692658628607
Accumulated other comprehensive income (loss)(66)(32)10(25)(41)(0)
Accumulated deficit(607)(490)(406)(276)(287)(378)
Other undisclosed equity, attributable to parent333333
Equity, attributable to noncontrolling interest(0)0(114)742115
Total equity:(110)20184367345347
TOTAL LIABILITIES AND EQUITY:3,5013,4733,7993,9404,0063,666

Income Statement (P&L) ($ in millions)
Annual | Quarterly

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues2,7942,3942,2122,0941,9931,626
Cost of revenue
(Cost of Product and Service Sold)		(1,774)(1,573)(1,416)(1,302)(1,330)(1,147)
Other undisclosed gross profit   (11)(23)(35)(126)
Gross profit:1,020821785769628353
Operating expenses(766)(632)(884)(603)(537)(602)
Other operating income, net 14   
Other undisclosed operating income (loss)(5)140(14)  
Operating income (loss):249204(95)15391(249)
Nonoperating income (expense)(304)(245)(153)(121)(127)28
Investment income, nonoperating     07
Gain (loss), foreign currency transaction, before tax(7)2(12)(0)16(5)
Interest and debt expense(5)(5)(5)(5)(9)(6)
Income (loss) from continuing operations before equity method investments, income taxes:(60)(45)(253)27(44)(227)
Other undisclosed income from continuing operations before income taxes555596
Income (loss) from continuing operations before income taxes:(55)(40)(248)31(36)(220)
Income tax expense (benefit)(19)(8)(7)(11)104(383)
Income (loss) from continuing operations:(74)(49)(255)2069(604)
Income (loss) before gain (loss) on sale of properties:✕✕✕✕2069(604)
Other undisclosed net income    5  
Net income (loss):(74)(49)(255)2069(604)
Net income (loss) attributable to noncontrolling interest(43)(35)125(10)22242
Other undisclosed net income (loss) attributable to parent  5(141)3  
Net income (loss) attributable to parent:(117)(79)(271)1391(362)
Preferred stock dividends and other adjustments   (0)   
Other undisclosed net income (loss) available to common stockholders, basic  (5)141(3)  
Net income (loss) available to common stockholders, diluted:(117)(84)(130)1191(362)

Comprehensive Income ($ in millions)
Annual | Quarterly

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(74)(49)(255)2069(604)
Comprehensive income (loss):(74)(49)(255)2069(604)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest(43)(25)90(27)65232
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(33)(53)7034(84)19
Comprehensive income (loss), net of tax, attributable to parent:(150)(127)(95)2750(353)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: